Orphan Drugs and Rare Diseases

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs.

Medical & Health Care

Submit new post
Thank you for posting.
Share it:

Key implementation of this will be a factor into further commercialisation and developments.

Based on this information SMi Group is proud to announce it will be hosting the 3rd annual conference on Orphan Drugs and Rare Diseases and bringing together leading experts and companies such as Novabiotics, Pfizer, AstraZeneca, GMP Orphan SAS, Genethon and M&C Saatchi and many more to discuss the latest developments in the market.

Benefits of Attending:

. Case Study: A patient representative giving an insight into their own thoughts on recruitment from start through to drug approval – engagement enhancement
. Just Released – The approval of the Early Access to Medicines Initiative, important insights from key opinion leaders
. Important! Focus is on enhancing development pathways of orphan indications, looking at initiatives and collaborations – What direction are we moving in?
. Assessing tools for consideration to gain early market access

Key Speakers:

. Dr Gunter Harms, Market Access & Public Affairs Directore, Shire
. Bertram Haussle, Chaiman of the Board of Management, IGES Institut
. Josie Godfrey, Associate Director-Highly Specialised Technologies, NICE
. Chris Hart, Information Practice Leader, AstraZeneca
. Anthony Hall, Co-Founder, Findacure Foundation

If you would like to attend this conference as a delegate please contact John Collins on +44 (0) 207 827 6734

If you are interested in sponsoring this event contact Alia Malick on +44(0)20 7827 6168

If you would like to become a media partner contact Sarah Watson on +44 (0)20 7827 6134

Conference only: 1499
Conference & 1 workshop: 2098
Conference & 2 workshops: 2697
One workshop only: 599
Two workshops only: 1198

From: October 20, 2014 08:30
To: October 21, 2014 17:30

Holiday Inn London - Regent's Park, Carburton St, W1W 5EE, United Kingdom


Medical & Health Care


drug development, early access initiatives, orphan drugs, patient engagement, pharma, pharmaceutical, rare diseases



Contact email

Contact phone
+44 020 7827 6734


Submitted by:

evvnt Platform

Are you the organizer?

Get in touch